Global trading
Key takeaways
- Eli Lilly and Company is a drug manufacturers - general business with stocks listed in the US.
- Eli Lilly and Company shares (LLY) are listed on the NYSE and all prices are listed in US Dollars.
- Its last market close was US$1354 - a decrease of 4.48% over the previous week.
Our top picks for trading platforms
Copy trading
Beginners
How to buy shares in Eli Lilly and Company
- Compare share trading platforms. To buy shares in a company listed in the USA from Australia you'll need to find a trading platform that offers access to USA stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Eli Lilly and Company. Find the share by name or ticker symbol: LLY. Research its history to confirm it's an investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eli Lilly and Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$1354, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Eli Lilly and Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Eli Lilly and Company. Optimise your portfolio by tracking how your stock performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Eli Lilly and Company shares
Compare other products
How we picked these
Finder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Must read
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Eli Lilly and Company overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Is it a good time to buy Eli Lilly and Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Eli Lilly and Company share price volatility
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$847.8335 up to US$1449.6801. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market ( average) beta is 1, while Eli Lilly and Company's is 0.389. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company financials
| Revenue TTM | US$86.5 billion |
|---|---|
| Operating margin TTM | 53.66% |
| Gross profit TTM | US$72.3 billion |
| Return on assets TTM | 21.06% |
| Return on equity TTM | 86.02% |
| Profit margin | 31.9% |
| Book value | 45.187 |
| Market capitalisation | US$1.3 trillion |
| EBITDA | US$46.5 billion |
TTM: trailing 12 months
Eli Lilly and Company share dividends
Dividend payout ratio: 21.66% of net profits
Recently Eli Lilly and Company has paid out, on average, around 21.66% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.49% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about 6.69 per share.
While Eli Lilly and Company's payout ratio might seem low, this can signify that Eli Lilly and Company is investing more in its future growth.
Eli Lilly and Company's next dividend payout is expected around 10 December 2026. To benefit from it's next dividend payout, you'll need to buy Eli Lilly and Company shares before 13 November 2026 (the "ex-dividend date").
Have Eli Lilly and Company's shares ever split?
Eli Lilly and Company's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares - just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Frequently asked questions
More resources on Finder
Ask a question
More guides on Finder
-
Revolut share trading review
Revolut now offers US stocks and crypto trades to Australian customers. Here are the pros and cons.
-
Sharesies review
Here's a detailed review of micro-investing app Sharesies plus its key features and pros and cons.
-
Bendigo Invest Direct share trading review
Your in-depth review of the Bendigo Invest Direct share trading service and what it offers for Aussie investors.
-
Marketech share trading review
We discuss the pros, cons, fees, features and other information about the online trading platform Marketech.
-
Superhero review: ASX and US share trading app
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
-
Sharesight stock portfolio tracker review
Sharesight is an online platform that helps investors track their overall stock portfolio performance including all dividends.
-
Stake review: A trading platform for AU and US stocks
Stake is a trading platform for Australians who want value for money when trading. Gain access to one of the cheapest CHESS-sponsored and US trading platforms in Australia, and $3 brokerage in the US.
-
St.George Directshares review
St.George directshares offers a fast and easy online platform to allow St.George, BankSA or Bank of Melbourne customers to trade shares and a range of other investments.
-
Bell Direct online share trading platform review
Bell Direct offers one-second placement guarantees for trades, so you can take advantage of all trading opportunities at the price you want.
-
Westpac Share Trading Account review
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.